EXOMEND LLC – Trademark Portfolio

Entity Type: 16

EXOMEND LLC holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MARKETSAUCE. The owner is based in Austin, TX.

Apt 247

2515 Elmont Drive

Austin, TX 78741

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

EXOMEND LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does EXOMEND LLC have?

EXOMEND LLC has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.

What trademark classes does EXOMEND LLC file in?

EXOMEND LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 35 covers advertising; business management; business administration; office functions.

What are EXOMEND LLC's most well-known trademarks?

EXOMEND LLC's registered trademark portfolio includes well-known marks such as MARKETSAUCE. These are among 1 currently registered trademark in the portfolio.

What is EXOMEND LLC's trademark registration success rate?

EXOMEND LLC has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.